☰

Ramon E. Parsons

Affiliations: 
Biochemistry and Molecular Biophysics Columbia University, New York, NY 
Area:
Molecular Biology, Oncology
Google:
"Ramon Parsons"
Mean distance: (not calculated yet)
 
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor

Children

Sign in to add trainee
Katrina Podsypanina grad student 2000 Columbia
Danny Liaw grad student 2001 Columbia
Ian A. Hennessy grad student 2002 Columbia
John A. Jakob grad student 2004 Columbia
Amy Gerstein Montia grad student 2007 Columbia
Lao H. Saal grad student 2007 Columbia
Barry M. Fine grad student 2008 Columbia
Cindy Hodakoski grad student 2012 Columbia
Maira M. Pires grad student 2013 Columbia

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Zhou RW, Parsons RE. (2023) Etiology of super-enhancer reprogramming and activation in cancer. Epigenetics & Chromatin. 16: 29
Kabir M, Sun N, Hu X, et al. (2023) Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53. Journal of the American Chemical Society
Cahuzac KM, Lubin A, Bosch K, et al. (2023) AKT activation because of PTEN loss upregulates xCT via GSK3β/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cells. Cell Reports. 42: 112536
Zhou RW, Xu J, Martin TC, et al. (2022) A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma. Nature Communications. 13: 6041
Yu X, Xu J, Cahuzac KM, et al. (2022) Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells. Journal of Medicinal Chemistry
Schoenfeld DA, Zhou R, Zairis S, et al. (2022) Loss of PBRM1 alters promoter histone modifications and activates ALDH1A1 to drive renal cell carcinoma. Molecular Cancer Research : McR
Yu X, Xu J, Xie L, et al. (2021) Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders. Journal of Medicinal Chemistry
Xu J, Yu X, Martin TC, et al. (2021) AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild-type KRAS and BRAF by destabilizing Aurora kinase B. Cancer Discovery
Pappas K, Martin TC, Wolfe AL, et al. (2021) NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer. Communications Biology. 4: 312
Molina-Sánchez P, Ruiz de Galarreta M, Yao MA, et al. (2020) Cooperation between distinct cancer driver genes underlies inter-tumor heterogeneity in hepatocellular carcinoma. Gastroenterology
See more...